These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 19325033)

  • 1. HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.
    Zhu J; Mactutus CF; Wallace DR; Booze RM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1071-83. PubMed ID: 19325033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.
    Midde NM; Gomez AM; Zhu J
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers.
    Xu C; Coffey LL; Reith ME
    Biochem Pharmacol; 1995 Jan; 49(3):339-50. PubMed ID: 7857321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 transgenic rats display an increase in [(3)H]dopamine uptake in the prefrontal cortex and striatum.
    Zhu J; Yuan Y; Midde NM; Gomez AM; Sun WL; Quizon PM; Zhan CG
    J Neurovirol; 2016 Jun; 22(3):282-92. PubMed ID: 26501780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons.
    Aksenov MY; Aksenova MV; Silvers JM; Mactutus CF; Booze RM
    Neurotoxicology; 2008 Nov; 29(6):971-7. PubMed ID: 18606182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of MDPV on dopamine transporter regulation in male rats. Comparison with cocaine.
    Lopez-Arnau R; Duart-Castells L; Aster B; Camarasa J; Escubedo E; Pubill D
    Psychopharmacology (Berl); 2019 Mar; 236(3):925-938. PubMed ID: 30284596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 5 inhibitors: inhibition of dopamine transporter activity.
    Price DA; Sorkin A; Zahniser NR
    Mol Pharmacol; 2009 Oct; 76(4):812-23. PubMed ID: 19628755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.
    Rothman RB; Ananthan S; Partilla JS; Saini SK; Moukha-Chafiq O; Pathak V; Baumann MH
    J Pharmacol Exp Ther; 2015 Jun; 353(3):529-38. PubMed ID: 25788711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding.
    Pristupa ZB; Wilson JM; Hoffman BJ; Kish SJ; Niznik HB
    Mol Pharmacol; 1994 Jan; 45(1):125-35. PubMed ID: 8302271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport.
    Midde NM; Yuan Y; Quizon PM; Sun WL; Huang X; Zhan CG; Zhu J
    J Neuroimmune Pharmacol; 2015 Mar; 10(1):122-35. PubMed ID: 25604666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling of the pH dependence of the binding of WIN 35,428 to the dopamine transporter in rat striatal membranes: is the bioactive form positively charged or neutral?
    Xu C; Reith ME
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1340-8. PubMed ID: 8819521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.
    Dutta AK; Xu C; Reith ME
    J Med Chem; 1998 Aug; 41(17):3293-7. PubMed ID: 9703474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of [3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats.
    Valchar M; Hanbauer I
    J Neurochem; 1993 Feb; 60(2):469-76. PubMed ID: 8419533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.
    Kopajtic TA; Liu Y; Surratt CK; Donovan DM; Newman AH; Katz JL
    J Pharmacol Exp Ther; 2010 Dec; 335(3):703-14. PubMed ID: 20855444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc modulation of drug binding, cocaine affinity states, and dopamine uptake on the dopamine uptake complex.
    Richfield EK
    Mol Pharmacol; 1993 Jan; 43(1):100-8. PubMed ID: 8423763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [3H]WIN 35,428 [2 beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane] binding to rat brain membranes. Comparing dopamine cell body areas with nerve terminal regions.
    Chen NH; Xu C; Coffey LL; Reith ME
    Biochem Pharmacol; 1996 Feb; 51(4):563-6. PubMed ID: 8619903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding domains for blockers and substrates on the dopamine transporter in rat striatal membranes studied by protection against N-ethylmaleimide-induced reduction of [3H]WIN 35,428 binding.
    Xu C; Coffey LL; Reith ME
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):64-73. PubMed ID: 9007844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909).
    Zhang Y; Rothman RB; Dersch CM; de Costa BR; Jacobson AE; Rice KC
    J Med Chem; 2000 Dec; 43(25):4840-9. PubMed ID: 11123994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells.
    Page G; Chalon S; Emond P; Maloteaux JM; Hermans E
    Neurochem Int; 2002 Feb; 40(2):105-13. PubMed ID: 11738476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
    Rothman RB; Dersch CM; Carroll FI; Ananthan S
    Synapse; 2002 Mar; 43(4):268-74. PubMed ID: 11835522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.